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situation.1. Introduction
Bone mineral density (BMD) testing by central dual-
energy x-ray absorptiometry (DXA) is the fundamental
technology for the diagnosis, treatment, and monitoring of
osteoporosis, and is a useful adjunct in the management of
other metabolic bone diseases [1e9]. The Canadian Asso-
ciation of Radiologists (CAR) BMD guidelines are issued
here as technical standards and represent the current expec-
tations for BMD testing and reporting in Canada. These
standards must be met to be accredited by the CAR BMD
Accreditation Program. Changes have been made to the 2010
CAR Technical Standards for Bone Mineral Densitometry
Reporting to incorporate principles from the 2010 Clinical
Practice Guidelines for the Diagnosis and Management of
Osteoporosis in Canada from Osteoporosis Canada:
Summary [1,2].ll rights reserved.
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Physicians
BMD consultation requests should include patient
demographics, the indication for BMD testing, factors of
relevance to scan assessment (joint replacement, bone
surgery, or bone disease in scan regions), osteoporosis
medication history, factors of relevance to fracture risk
determination in patients 50 years old or older (fragility
fracture history, glucocorticoid history), and any other
pertinent medical information [1,2,6,10]. On follow-up scans
done on patients receiving osteoporosis drug therapy, it is
particularly helpful if BMD requests indicate the scan year of
primary interest for comparison, with details of current
osteoporosis drug therapy and duration [2,6,11,12]. Although
this level of information is often not provided, a thorough
patient history from the referring physician is to be encour-
aged [1,2,6].
3. Adult Patient Questionnaire
A template questionnaire that acquires the appropriate
information necessary for BMD testing in adults (defined as
those 18 years old or older) is presented in Appendix 1 [1,2].
This questionnaire can either be filled in by patients and then
clarified by trained facility staff or a history can be directly
taken by facility staff. The specific items on the question-
naire are intended to collect the minimum information
needed to analyse a BMD scan and determine absolute
fracture risk in those 50 years old or older [1,2]. Additional
history items that are of relevance to individual patients
should also be collected, such as menopausal history, medi-
cation history, and illnesses [1,2,6].
4. BMD Report Contents
Report contents will differ, depending on whether it is an
adult (18 years old or older) or a pediatric study that is being
reported and whether it is a baseline or follow-up study.4.1. Components of a First-Time Adult BMD ReportThe components of a first-time adult BMD report are
shown in Appendix 2 [1,2].
4.1.1. Demographics
Demographics should include patient name, date of birth,
sex, provincial health care number or other identifier, height,
weight, scan date, report date, name of the referring physi-
cian, name of the reporting physician, and BMD facility
name and location [2,6,13]. Weight and height should be
measured at the BMD facility [1,2]. Neither values reported
by the patient nor measurements provided by other medical
practitioners should be used, other than in exceptional
circumstances in which it is not possible to carry out the
measurements (such as if the patient cannot stand). If heightor weight data were not measured directly by the BMD
facility, then this should be indicated in the report.
Weight can be measured with either a mechanical or an
electronic scale that is medical grade. Facilities are encour-
aged to use wall-mounted height measuring devices, referred
to as stadiometers, and to use standardized positioning of
patients [7,14,15]. It also is encouraged that 3 height
measurements be made, with repositioning between each
measurement and that the average be used as the height
value. The reason for this is that, just as with bone density
quantitation, height measurements have significant precision
error, and this is minimized by averaging several assessments
[14,15]. Currently, this height measurement methodology is
a recommendation and is not a requirement for accreditation.4.1.2. Diagnostic category
The current standard for reporting the diagnostic category
is shown in Appendix 3 [2]. The diagnostic category is
determined by using the lowest T-score (for individuals 50
years old or older) or Z-score (for individuals younger than
50 years of age) from the available results for the lumbar
spine, total hip, femoral neck, 1/3 (or 33%) radius, and total
body (see section BMD Data and Appendix 3 for details) [2].
The trochanteric region and Ward’s region of the proximal
femur are not to be used [16]. T-scores or Z-scores for
diagnostic categorization should be derived by using a white
female reference database for women and a white male
reference database for men.4.1.3. Fracture risk category
The absolute fracture risk category should be reported for
men and women 50 years old and older when a relevant
history is available [1,2]. The current standard for deter-
mining absolute fracture risk uses the 2010 version of the
CAR/Osteoporosis Canada risk tables (CAROC 2010) [1,2].
The CAROC 2010 risk tables are provided in Appendix 4,
along with instructions on how to use them. This risk
determination incorporates BMD results from the femoral
neck, age, sex, fragility fracture history after age 40 years,
and glucocorticoid history. The spine BMD T-score also is
used in certain circumstances. There are several clinical
circumstances in which the fracture risk is deemed to be
high, regardless of BMD. There also are clinical circum-
stances in which fracture risk cannot be assigned. Details are
provided below. For individuals younger than age 50 years
old, absolute risk assessment is not available, and a fracture
risk category should not be reported [13,16].
CAROC 2010 table. Fracture risk is determined on the
CAROC 2010 tables by using the femoral neck T-score. For
both women and men, T-scores for fracture risk determina-
tion by using CAROC 2010 are derived from a white female
reference database. Note that this approach differs from that
used to determine the diagnostic category for men (section
Diagnostic Category), in which a white male reference
database is used. BMD data for males, therefore, will need to
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databases.
Fragility fracture history. The absolute fracture risk
categories were derived by using data from 4 types of frac-
tures: forearm, vertebra, proximal femur, and proximal
humerus [3]. Fractures at these sites should generally be
regarded as fragility fractures if they occur subsequent to
a fall from standing or sitting heights. Generally, craniofacial
fractures and fractures of the hands and feet are not considered
fragility fractures. Other types of fractures have weaker rela-
tionships to osteoporosis but may be regarded as fragility
fractures if the history suggests that the fracture occurred with
a degree of trauma that would not normally be expected to
lead to a broken bone [2,17]. Only fractures that occurred after
age 40 years should be considered in determining risk [2,17].
Glucocorticoid history. Glucocorticoid history is
considered positive if prednisone (or other glucocorticoids in
terms of prednisone equivalents) was in use at a dose equal to
more than 7.5 mg per day for more than 3 cumulative months
in the prior 12 months (ie, for more than 90 total days of the
preceding 365 days, not necessarily consecutive) [1,2].
Patients with hypoadrenalism and who are on replacement
glucocorticoids should not be considered to have a positive
glucocorticoid history for fracture risk determination
regardless of glucocorticoid dose [18].
High risk regardless of BMD. There are several clinical
situations that relate to fracture history in which an indi-
vidual should be classified as having a high fracture risk
regardless of the BMD result. These include a history of 1
fragility fracture and a positive glucocorticoid history,
history of fragility hip fracture, history of fragility vertebral
fracture, and history of 2 or more fragility fractures [1,2].
Use of the spine T-score. If the fracture risk category has
been determined to be low after determining the fracture risk
category when using the femoral neck T-score on the
CAROC 2010 table, fracture history, and glucocorticoid
history, the spine T-score is assessed. If the spine T-score is
less than or equal to -2.5, then the risk category is increased
to moderate [1,2]. A white male reference database is used
for this purpose for men, and a white female reference
databases used for women.
Use of sites other than femoral neck and spine. Sites
other than the femoral neck and the spine are not used to
generate the fracture risk category, although they are used for
determining diagnostic category [1,2].
Undefined clinical scenarios. When using the approach
of Osteoporosis Canada, it will not be possible to generate
a fracture risk category in certain clinical scenarios [1,2]. In
particular, this will occur when the femoral neck and the
spine are not available or when the femoral neck is not
available while the spine is available but has a T-score higherthan 2.5. In addition, there are scenarios in which the frac-
ture risk is likely higher than determined by the femoral neck,
as when the spine T-score is much lower than2.5 or T-scores
of other skeletal sites are much lower than the value at the
femoral neck. In these circumstances, the reporting physician
should provide guidance in the interpretation section.
Use of FRAX. Although FRAX (the World Health
Organization fracture risk system) has validity for fracture
prediction, both Osteoporosis Canada and CAR have
endorsed CAROC 2010 as the method of choice for reporting
BMD results [1e3,19e26]. CAROC 2010 is to be used for
fracture risk reporting [1,2].
Integrating fracture risk determination by using the
Osteoporosis Canada paradigm. A flow chart of one
approach to systematically integrating these principles is
provided in Appendix 5.Bone-active drug therapy. Bone-active drug therapymay
alter fracture risk if the drug is taken regularly, if it is taken
correctly, and if it is achieving thedesired effects, although some
evidence that indicates that fracture risk determination might
remainvalid in the short term, evenwhenmedications are in use
[2,27,28]. If a patient who undergoes BMD testing for the first
time is already on bone-active drug therapy, then the fracture
risk category should be provided, but a statement should be
included that indicates that the riskmaybe lower than calculated
if osteoporosis drug therapy is effective [1,2,28].
4.1.4. History used for risk determination
For individuals 50 years old and older, the report should
state the specific history used in risk determination when
either the fragility fracture status or the glucocorticoid
history is positive [1,2]. This transparency allows the refer-
ring physician to understand how the fracture risk was ach-
ieved and allows the referring physician to provide
clarification or additional information if appropriate.
4.1.5. BMD data
Care must be taken in all technical aspects of how scan-
ning is performed, including adherence to manufacturer
protocols, proper positioning, subregion assignment, bone
tracing, determination of regions of interest, and quality
assurance [2,6,13]. A minimum of 2 skeletal sites should be
scanned and reported [2,6,9]. The usual sites would be the
lumbar spine and the proximal femur [2,6,9]. When ana-
lysing the lumbar spine, L1 to L4 should be used unless the
decision is made to exclude 1 or 2 vertebrae because of
technical artifacts [2,13]. A minimum of 2 vertebrae should
be used. Interpretation should not be based on a single
vertebra [2,13]. If a report includes graphic representation of
results, then the graph must present data and reference curves
for the vertebrae actually used in interpretation [29].
Consideration can be given to excluding a particular vertebra
if the T-score of that vertebra is more than 1 standard
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highest value [29]. It is not mandatory that a high-density
vertebra be excluded, but it should be evaluated for causes
of artifact, and a decision should be made as to whether it
should be retained in the vertebral analysis.
For the proximal femur, the left side should be measured
unless it is not available or is invalid, or if the right hip was
previously measured [2]. Results should be reported for the
total hip and femoral neck [2,13]. If either the spine or the
hip site is not available or is invalid because of artifact,
another site should be substituted [2,6,13]. The nondominant
forearm is the site of choice and the 1/3 (or 33%) radius
should be reported [2,6,13]. If the nondominant forearm is
not available or is invalid, then the dominant side may be
used. If the wrist cannot be measured, then the total body
BMD can be assessed [29]. The head may be included or
excluded when analysing the scan. If the head is excluded,
then this should be noted in the report. If the spine cannot be
measured and neither forearm nor total body measurements
are available, then bilateral hip measurements may be made
[6,13,29]. The 2 hip measurements should be reported
separately, not as an averaged value [29]. When applying hip
data to determine the diagnostic category or fracture risk
category, the lowest of the relevant values from the 2 sides
should be used. For patients whose weight exceeds the limit
of the DXA equipment, bilateral forearm studies may be
done unless 1 side is not available or is invalid, although it
will not be possible to determine fracture risk [29].
For each skeletal site with a valid scan, reported density
results should include absolute BMD (in g/cm2, to 3 decimal
places) and either a T-score (to 1 decimal place) for those 50
years old or older, or a Z-score (to 1 decimal place) for those
younger than 50 years of age [10,13,16,29]. For women,
T-scores and Z-scores should be derived by using the
manufacturer’s white female reference database. For men
older than age 50 years, T-scores used for diagnostic clas-
sification should be derived by using a white male reference
database; the femoral neck T-score used for risk determina-
tion should be derived from a white female reference data-
base, whereas the spine T-score used to alter the risk category
from low to moderate if the value is less than or equal to -2.5
should be derived from a white male reference database.
Both femoral neck T-scores must be reported. For men
younger than age 50 years old, Z-scores should be derived by
using a white male reference database. Nonwhite reference
databases should not be used. The reference databases and
versions should be specified in the report [6,29].
4.1.6. Limitations
Any structural abnormalities, anatomic variants, artifacts,
suboptimal positioning, or other issues that impact scan
reliability and interpretation need to be considered when
interpreting BMD results [2,6,10,13]. A judgement needs to
be made as to whether these issues render results invalid or
impact on the interpretation. Some sources of artifact are
preventable, and care should be taken to assess these before
scanning (such as metal on clothes or in pockets, or recentbarium or nuclear medicine studies) and either remove the
source of artifact or postpone the scan to a future date.
Sources of artifact relevant to the scan should be noted in the
report. Skeletal size can affect BMD readings, with larger
bones producing falsely high values and smaller bones
producing falsely low values [29]. There is no accepted
means of correcting for skeletal size, but height or weight
outside the normal range should be noted and should be
considered in the interpretation of results.
4.1.7. Interpretation
A narrative section on interpretation and implications of
BMD results should be provided. This should not be a simple
restatement of data. In individuals older than age 50 years in
whom an absolute fracture risk cannot be assigned by using
the Osteoporosis Canada paradigm, the reporting physician
should integrate the available information and provide an
indication of fracture risk when this is possible. Guidance as
to therapeutic considerations can also be provided within the
context of Osteoporosis Canada guidelines to the degree
appropriate to the knowledge and experience of the reporting
physician [1,2].
4.1.8. Recommended follow-up date
A recommendation should be included for the timing of the
next DXA study [2,13]. The timing of serial testing should be
driven by the expected rate of bone loss. The intention of serial
monitoring is to provide a sufficient period of time for antic-
ipated changes in density to exceed the precision error of the
DXA method, which also renders a stable density informative
[1,2,4,6,13]. A guide is provided in Appendix 6, although this
needs to be applied in the context of local provincial health
insurance plan restrictions. When indicating recommended
timing of the subsequent BMD test, consideration should be
given to specifying the year of recommended follow-up rather
than a time interval because this makes the report more readily
implementable by referring physicians. For follow-up periods
of less than 2 years, the month of recommended follow-up
could also be included. This approach is not a requirement
for accreditation at this time.
4.1.9. Definitions
Any terminology or abbreviation used in the report should
be defined. Some examples are the following:
T-score: The number of standard deviations above (þ) or
below () the mean peak density.
Z-score: The number of standard deviations above (þ) or
below () the mean density for an individual of that age
and sex.
Fracture risk: High fracture risk is 10-year absolute
fracture risk >20%; moderate fracture risk is a 10-year
absolute fracture risk in the range of a 10%-20%; low
fracture risk is a 10-year absolute fracture risk <10%.
TBLH: Total body less head, assessment of the entire
body minus the head region.
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Machine identification should include DXA brand, model,
and serial number.4.2. Components of a Follow-up Adult BMD ReportThe components of a follow-up adult BMD report are
shown in Appendix 7. A follow-up adult BMD report should
include all the components of a first-time adult report. In
addition, items specific to follow up also need to be
described, including changes in density, statistical parame-
ters that relate to measurement error, aspects of interpretation
that relate density changes to the clinical situation, and
definitions relevant to follow up.
4.2.1. Demographics
Change in height as measured at the BMD facility should be
noted [1,2,13,15]. In particular, measured height loss that
exceeds 2 cm over 3 or fewer years should be emphasized
because this amount of height change has been shown to have
a high predictive value for incident vertebral fractures that have
developedduring themonitoringperiod [2,15],whichmaybean
indication to perform spine radiographs or vertebral fracture
assessment byDXA [2]. Change in weight should also be noted
because this can create artifactual changes in BMD values
[2,30]. There is no consensus as towhat the threshold should be
for flagging a change in weight as being of potential importance
as a source of artifact, with some physicians using percentage
change in weight and others using absolute change in weight. A
suggested threshold is 10% change in weight over the period of
monitoring [29]. The use of thisweight-change threshold is only
a recommendation and is not a requirement for accreditation.
Each reporting physician, however, must define a weight-
change threshold and use it in all serial reporting and apply it
to each pair ofBMDmeasurements forwhich change inBMD is
reported.
4.2.2. Fracture risk category
The absolute fracture risk category should be reported for
men and women 50 years old and older, regardless of the
therapy that may be in use [1,2]. If bone-active drug therapy
is in use, then the fracture risk category should be provided,
but a statement should be included that indicates that the risk
may be lower than calculated if osteoporosis drug therapy is
effective [1,2].
4.2.3. Changes in density
When comparing serial assessments, the same machine
should be used when possible [2,12,13], and positioning and
subregion assignment must be consistent [2,12,13]. The same
reference population database should be used for serial studies
when possible [29]. If the reference database must be changed,
this should be noted in the report. The description of density
change should include the absolute density change (in g/cm2,
to 3 decimal places) and percentage change (to 1 decimal
place) [10,13,29]. Percentage changemust be derived by using
absolute density (g/cm2), not T-scores or Z-scores [4]. Anannualized rate of change may be reported, but this is optional.
The skeletal sites for which changes in density are to be re-
ported are the lumbar spine (by using whichever vertebrae are
considered valid, with a minimum of 2 vertebrae) and the total
proximal femur [2,13]. Hip subregions should not be used [2].
If either the spine or the hip is not available, then it is
permissible to report changes at a single site. If the forearm or
total body BMD is being monitored in lieu of the spine or hip,
then the change can be reported for the 1/3 (or 33%) proximal
radius or for the total bodyBMD [10,29]. Itmust be recognized
that the change profile at these sitesmay not parallel changes at
the spine and hip, and may not correlate as well with drug
responses [10,29]. This will need to be addressed in the
interpretation section.
Changes in density must be reported in relation to (1) the
first study on file, (2) themost recent previous study, and (3) the
study done closest to the initiation of the current clinical
treatment regimen (if any), if this can be ascertained. The latter
BMD change is the one of greatest importance for patients on
drug therapy; it also is relevant to patients who started lifestyle
and nutritional supplements for bone health [1,2]. Ideally, the
comparison study of primary interest should be indicated on
the requisition by the referring physician, but, if it is not
provided, then the reporting physician is responsible for
obtaining this information by patient history.
Statistical significance must be reported for each BMD
skeletal-site comparison, and must indicate whether the
difference is considered significant at a 95% level of confi-
dence [2,4,6]. The manufacturer’s software determination of
statistical significance is not to be used [2]. Each facility must
determine precision error for each DXAmachine and for each
skeletal site (including the forearm and the total body if these
sites are measured by the facility and are used for serial
monitoring) by using the least significant change (LSC)
methodology and use this value when determining statistical
significance [2,13]. It is permissible to apply results derived
from precision testing on 1 side (forearm or hip) to serial scans
done by using the opposite side of the body [13]. A follow-up
BMD report should state the LSC in absolute values (g/cm2, to
3 decimal places) for each skeletal site for which change is
reported [10,13,29]. Whenever possible, the same instrument
should be used for serial studies of an individual patient [29].
Comparisons between measurements done on different
machines can be made only if intermachine precision between
the 2 devices has been determined [13,29].
4.2.4. Interpretation
The clinical implications of density change or stability
must be incorporated into the interpretation section of the
report [1,2,6,29]. This is of greatest importance for patients
who are using osteoporosis drug therapy, when BMD is often
being used to assist in monitoring drug actions [1,2,10]. The
primary BMD outcome of interest in this circumstance is the
net change in density from the time that the current drug
regimen was initiated [1,11]. In general, net stability or
a gain in density is considered a positive drug effect, whereas
net loss of density is considered evidence of drug failure
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differ from the net change on a drug regimen, such as
a change from the most recent prior study, also need to be
considered in the interpretation [31]. For serial studies in
those patients not on osteoporosis drug therapies, there are
similar implications for the effects of nutritional supple-
ments, lifestyle changes, and exercise regimens [1,11].
There are insufficient data at this time to define the
relationship between the amount of loss and the resulting
change in fracture risk, so loss of density is not incorporated
into the absolute fracture risk methodology [32]. The re-
ported absolute fracture risk should not be altered because of
loss in density. Rather, the implications of density loss
should be discussed in the interpretation of results.
4.2.5. Definitions
LSC Least significant change is the amount by which 1
BMD value must differ from another for the difference to
be statistically significant at a 95% level of confidence.4.3. Components of a First-Time Pediatric BMD ReportThe pediatric population is defined as individuals younger
than 18 years old. The components of a first-time pediatric
BMD report are shown in Appendix 8. Components that are
similar to the content of an adult first-time BMD report
include demographics, machine identification, and limitations
[1,2,6,7,13,33]. There are differences concerning BMD data
and interpretation, and specific definitions apply to reporting
in this age group [6,7,13,33,34]. There are no guidelines on
timing of follow-up studies, so a recommended follow-up date
is not mandatory, although it may be included at the discretion
of the reporting physician [7,29,33]. A pediatric history sheet
is not provided because there are no mandatory items incor-
porated into the report (as with adult absolute risk determi-
nation), but the adult history sheet can be adapted. A history
that is relevant to the individual pediatric patient should be
collected and may include fracture history, medications, and
illnesses [7,13,33]. Height and weight measurements in
younger children require special devices and procedures [33].
If these are not available, then it is acceptable in younger
children to use values provided by other medical practitioners.
If height or weight were not measured directly by the BMD
facility, then this should be indicated in the report.
4.3.1. Diagnostic category
The current standard for reporting the diagnostic category
in the pediatric population is shown in Appendix 3 [2,29].
The diagnostic category is based on the lowest adjusted
Z-score from the results for the lumbar spine and total body
by using either bone mineral content (BMC) or BMD at the
discretion of the reporting physician [6,7,13,29,33]. See
section BMD Data for clarification of Z-score adjustment.
The T-score is not to be used in pediatric reporting
[7,13,29,33]. If either the spine or the total body value is not
available or is invalid, then this should be reported as
a limitation. Forearm measurements (1/3 or 33% of the site)may be used if either the spine or the total body value is not
available but only if a reference population database is
available from which forearm Z-scores can be derived
[6,7,13,29,33]. Proximal femur measurements are not to be
used to generate the diagnostic category in the pediatric
population, although it may be clinically useful to begin
measuring hip density in older adolescents to transition into
the adult mode of monitoring [2,13,29,33].
4.3.2. BMD data
Care must be taken in all technical aspects of how scan-
ning is performed, including adherence to manufacturer
protocols, proper positioning, subregion assignment, bone
tracing, determination of regions of interest, and quality
assurance [6,7,13,29,33]. Results should be reported for the
lumbar spine and the total body, including BMC and BMD for
each site [7,13,29,33]. When analysing the lumbar spine, L1
to L4 should be used unless the decision is made to exclude 1
or 2 vertebrae because of technical artifacts [2,29]. A
minimum of 2 vertebrae should be used [2,29]. Interpretation
should never be based on a single vertebra [2,29]. If a report
includes graphic representation of results, then the graph must
present data and reference curves for the vertebrae actually
used in interpretation [2,29]. Consideration can be given to
excluding a particular vertebra if the Z-score of that vertebra
is more than 1 standard deviation more than the Z-score of the
vertebra with the next highest value [29]. It is not mandatory
that the high-density vertebra be excluded, but it should be
evaluated for causes of artifact and a decision made as to
whether it should be included in the vertebral analysis. On
some manufacturers’ databases, Z-scores may not be available
if vertebrae are excluded. In this circumstance, it is appro-
priate to include L1 to L4 to generate a Z-score, but the
interpretation section must address the accuracy of the spine
measurement and the ways in which the Z-score may have
been perturbed by the abnormal vertebrae. For the total body
measurement, the head may be included or excluded when
analysing the scan [6,29,33,34]. If the head is excluded, then
this should be noted in the report. For adolescent patients
whose weight exceeds the limit of the DXA equipment,
bilateral forearm studies may be done unless one side is not
available or is invalid, in which case a single side can be
measured [29,33,34].
For each skeletal site with a valid scan, reported density
results should include the absolute BMD (in g/cm2, to 3
decimal places), the BMD Z-score (to 1 decimal place), and
the adjusted BMD Z-score (to 1 decimal place); and the
BMC (in grams, to 2 decimal places), BMC Z-score (to 1
decimal place), and adjusted BMC Z-score (to 1 decimal
place) [6,13]. The Z-score adjustment is done to correct for
relative skeletal size or maturation. There is no consensus at
this time as to the specific adjustment that should be made, so
the nature of the adjustment is at the discretion of the
reporting physician. Adjustment can be based on height,
weight, body mass index, bone area, bone age, pubertal
stage, lean body mass, or a combination of these parameters
[6,7,13,29,33e41]. The method of adjustment should be
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then a published reference should be provided. The assign-
ment of diagnostic category should be based on the adjusted
Z-scores by using the BMC Z-score, the BMD Z-score, or
the lower of the 2, at the discretion of the reporting physi-
cian. Some manufacturers provide height or weight correc-
tions as part of the DXA software. For those whose DXA
software does not provide such corrections, an approach to
correcting for bone age or height age is described in
Appendix 9 [7,29,33]. Each method of correction has limi-
tations and constraints, and these need to be considered in the
interpretation [29,33].
Bone area, corrected bone area, and area Z-scores are not
required but can be included at the discretion of the reporting
physician [7,13,29,33,42]. All Z-scores should be derived by
using a white female reference database for girls and a white
male database for boys [29]. Nonwhite reference databases
should not be used. The reference database and version
should be specified in the report [6,7,29,33]. If the reference
database that is used to generate Z-scores is not one provided
by the manufacturer, then a published reference should be
provided. Z-scores may not be available for certain skeletal
sites at young ages and so do not need to be reported.
4.3.3. Definitions
Any terminology or abbreviations used in the report
should be defined.4.4. Components of a Follow-up Pediatric BMD ReportThe components of a follow-up pediatric BMD report are
shown in Appendix 10. A follow-up pediatric BMD report
should include all of the components of a first-time pediatric
report. In addition, items specific to follow-up also need to be
described, including changes in density, statistical parame-
ters that relate to measurement error, and aspects of inter-
pretation that relate to the changes in density.
4.4.1. Changes in density
When comparing serial assessments, positioning and
subregion assignmentmust be consistent [29,40,41]. The same
reference population database should be used for serial studies
whenever possible [13,33]. If the reference population data-
base must be changed, then this should be noted in the report.
The description of density change should include the absolute
density change (in g/cm2, to 3 decimal places), percentage
change (to 1 decimal place, derived by using absolute density,
not Z-scores), change in Z-score, and change in adjusted Z-
score [13,29]. Annualized rates of changemay be reported, but
this is optional [29,42]. The skeletal sites for which changes in
density are to be reported are the lumbar spine (by using
whichever vertebrae are considered valid, with aminimumof 2
vertebrae) and the total body [29,33,34]. If the forearm is being
monitored in lieu of the spine or the total body, then change can
be reported for the 1/3 or 33% proximal radius [29,34,40]. It
must be recognized that the change profile at the forearm may
not parallel changes at the spine and total body, and may notcorrelate as well with drug responses. This will need to be
addressed in the interpretation section, if applicable.
Changes in density must be reported in relation to (1) the
first study on file, and (2) the most recent previous study.
Pediatric osteoporosis drug treatment regimens are not well
defined, and, if information is not provided by the referring
physician, then it can be difficult to ascertain the timing of
the BMD study that corresponds to the initiation of a clinical
treatment regimen. It is therefore not mandatory at this time
that changes be reported in relation to the initiation of
treatment. This can be provided at the discretion of the
reporting physician if it is thought that an appropriate
comparison study can be defined in relation to treatment.
Statistical significance must be reported for each BMD
skeletal site comparison, which indicates whether the
difference is considered significant at a 95% level of confi-
dence [29,33,43]. The manufacturer’s software determination
of statistical significance is not to be used [13,29]. Each
facility must determine precision error for each DXA
machine and for each skeletal site (including the forearm if
this site is measured by the facility and used for serial
monitoring) by using the LSC methodology and use this
value when determining statistical significance [13,29,33]. It
is permissible to apply results derived from precision testing
of the forearm on one side to serial scans done by using the
opposite side of the body. Facilities are encouraged to derive
precision by using pediatric-age subjects, particularly facil-
ities that perform only pediatric clinical tests. In the absence
of data that proves that precision differs between adults and
children, however, it is acceptable at this time for all facili-
ties to use precision derived from adult subjects [29,33]. If
precision is derived by using adult subjects, then this should
be noted in the report. A follow-up pediatric BMD report
should state the LSC in absolute values (g/cm2, to 3 decimal
places for BMD; grams, to 2 decimal places for BMC) for
each skeletal site for which change is reported and for both
BMD and BMC [13,29]. Whenever possible, the same
instrument should be used for serial studies on an individual
patient [29]. Comparisons between measurements done on
different machines can be made only if intermachine preci-
sion between the 2 devices has been determined [13,29].
There is no accepted methodology at this time for eval-
uating the statistical significance of Z-score differences at
different time points. The change in Z-score between
comparison BMD studies should be noted. An opinion as to
whether the difference is clinically meaningful should be
incorporated into the Interpretation section. It is not neces-
sary to report changes in either height or weight.References
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Appendix 1. Patient Questionnaire
Please complete this questionnaire while waiting for your bone mineral density test. 
This document will be reviewed with you. A staff member will measure your height and weight.
Name ______________________________________ Date ___________________
Date of birth _________________________________ Female Male
If you answer yes to any of the following 3 questions, please speak to the receptionist 
immediately: 
1. Is there any chance that you are pregnant? Yes No
2. Have you had a barium enema or barium drink in the past 2 weeks? Yes No
3. Have you had a nuclear medicine scan or x-ray dye in the past week? Yes No
The following information will help us to assess your future risk for fracture. 
4. Have you ever had a bone density test before? Yes No
If yes, when and where? __________________________________
5. Have you ever had surgery of the spine or hips? Yes No
6. Have you ever broken any bones? Yes No
If yes, please state:
Bone Broken Age Bone Broke Cause of Broken Bone
7. Have you taken steroid pills (such as prednisone or cortisone) for more 
than 3 months in the past 12 months?
Yes No
If yes, are you currently taking steroid pills? Yes No
How long have you been taking them? __________________________
What is your current dose? ___________________________________
What is the reason that you take steroid pills?_____________________
Yes No8. Have you ever been treated with medication(s) for osteoporosis?
If yes, which medication(s) and for how long?
Do not write in this box
Additional History
Reviewed by: Signature:
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Mineral Density Report
All first-time adult (18 years old or older) bone mineral
density (BMD) reports should include the following
components in this recommended order of presentation:
Demographics
A name
A date of birth
A sex
A provincial health care number or other identifier
A height
A weight
A scan date
A report dateA referring physician
A reporting physician
A facility name and location
Diagnostic Category
Fracture Risk Category (if 50 years old or older)
History Used for Risk Determination
BMD Data
A BMD
A BMD T-score for those 50 years of age or older/Z-
score for those younger than age 50 years
A reference database used
Note: For men 50 years of age or older, there will be 2
sets of BMD T-scores and 2 reference databases listed:
a white male reference database for diagnostic catego-
rization and a white female reference database for risk
determination.
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Interpretation
Recommended Follow-up Date
Definitions
Machine Identification
A brand
A model
A serial numberAppendix 3. Bone Mineral Density Diagnostic CategoriesPatient group Category name T-score value Z-score value
50 years old and 
older
Normal –1.0
Low bone mass Between –1 and –2.5
Osteoporosis –2.5
Younger than 50 
years old
Within expected 
range for age
> –2.0
Below expected 
range for age
–2.0For adults 50 years of age and older, the diagnostic
category is determined by using the lowest T-score for the
lumbar spine, total hip, femoral neck, 1/3 (or 33%) radius,
and total body. T-scores are derived by using a white female
reference database for women and a white male reference
database for men.
For adults aged 18 years to younger than 50 years old, the
diagnostic category is determined by using the lowest Z-
score for the lumbar spine, total hip, femoral neck, 1/3 (or
33%) radius, and total body. Z-scores are derived by using
a white female reference database for women and a white
male reference database for men.
For children, defined as being younger than age 18 years
old, the Z-scores require adjustment for one or more of
height, weight, body mass index, bone area, bone age,
pubertal stage, and lean body mass. The diagnostic category
is determined by using the lowest adjusted Z-score for the
lumbar spine and total body. Z-scores are derived by using
a white female reference database for girls and a white male
reference database for boys.Appendix 4. How to Determine an Individual’s 10-Year
Absolute Fracture Risk
1. Begin with the table appropriate for the patient’s sex.
2. Identify the row that is closest to the patient’s age.
3. Determine the individual’s fracture risk category by
using the femoral neck T-score.
4. For ages intermediate between values in the table,
interpolate T-score thresholds.
5. If either fragility fracture history or glucocorticoid
history is positive, then the individual is moved up to the
next highest risk category.
6. Fracture risk for an individual is high regardless of the
CAROC 2010 risk result when both fragility fracture history after age 40 years and
glucocorticoid history are positive
 there has been a fragility hip fracture after age 40
years
 there has been a fragility vertebral fracture after age
40 years
 there have been 2 or more fragility fractures after
age 40 years.
7. If the fracture risk category is low after these steps, then
the lumbar spine T-score is considered (by using a white
male reference database for men and a white female
reference database for women). If the lumbar spine
T-score is  2.5, then the risk is increased to moderate.
CAROC 2010 Ten-Year Fracture Risk for Women
Femoral neck T-scoreAge (y) Low risk (<10%) Moderate risk
(10% to 20%)High risk (> 20%)50 Greater than 2.5 2.5 to 3.8 Less than 3.8
55 Greater than 2.5 2.5 to 3.8 Less than 3.8
60 Greater than 2.3 2.3 to 3.7 Less than 3.7
65 Greater than 1.9 1.9 to 3.5 Less than 3.5
70 Greater than 1.7 1.7 to 3.2 Less than 3.2
75 Greater than 1.2 1.2 to 2.9 Less than 2.9
80 Greater than 0.5 0.5 to 2.6 Less than 2.6
85 Greater than þ0.1 þ0.1 to 2.2 Less than 2.2CAROC 2010 Ten-Year Fracture Risk for Men
Femoral neck T-scoreAge (y) Low risk (<10%) Moderate risk
(10%-20%)High risk (>20%)50 Greater than 2.5 2.5 to 3.9 Less than 3.9
55 Greater than 2.5 2.5 to 3.9 Less than 3.9
60 Greater than 2.5 2.5 to 3.7 Less than 3.7
65 Greater than 2.4 2.4 to 3.7 Less than 3.7
70 Greater than 2.3 2.3 to 3.7 Less than 3.7
75 Greater than 2.3 2.3 to 3.8 Less than 3.8
80 Greater than 2.1 2.1 to 3.8 Less than 3.8
85 Greater than 2.0 2.0 to 3.8 Less than 3.8Values in the table are taken from the Osteoporosis Canada 2010 guidelines
for the assessment of fracture risk (Ref. 2).
Notes
For both women and men, the femoral neck T-score used
to determine fracture risk must be derived by using a white
female reference database. If the femoral neck T-score
produces a low risk of fracture and a spine T-score of 2.5 or
less is used to assign fracture risk, then the spine T-score is
derived from a white female reference database for women
and a white male reference database for men.
Fractures of the forearm, vertebra, proximal femur, and
proximal humerus are usually fragility fractures if they
occurred subsequent to a fall from a standing or sitting height.
Generally, craniofacial fractures and fractures of the hands and
feet are not considered fragility fractures. Other types of
fractures may be regarded as fragility fractures if the history
291CAR technical standards for BMD reporting / Canadian Association of Radiologists Journal 64 (2013) 281e294suggests that the fracture occurred with a degree of trauma that
would not normally be expected to lead to a broken bone.
Glucocorticoid history is considered positive if predni-
sone (or other glucocorticoids in terms of prednisone
equivalents) was in use at a dose 7.5 mg per day for moreAppendix 5. The Osteoporosis Canada Approach to Determi
Osteoporosis Canada Approach for Risk Determination
GH = glucocorticoid history (7.5 mg/d prednisone or equivalent for 3 cumulativ
The initial risk category by using CAROC 2010 is derived from the T-score for
For both women and men, the femoral neck T-score used to determine fracture ris
neck T-score produces a low risk of fracture and a spine T-score of -2.5 or less i
female reference database for women and a white male reference database for mthan 3 cumulative months in the prior 12 months. Patients
with hypoadrenalism on replacement glucocorticoids should
not be considered to have a positive glucocorticoid history
for fracture risk determination regardless of glucocorticoid
dose.ning an Individual’s 10-Year Absolute Fracture Risk
e months in the prior year).
the femoral neck.
k must be derived by using a white female reference database. If the femoral
s used to assign fracture risk, then the spine T-score is derived from a white
en.
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Mineral Density TestsExpected rate of
BMD changeClinical example Timing of
follow-upVery high Moderate-to-high dose of glucocorticoids,
anabolic agent6-12 moHigh Osteoporosis drug therapy initiated or
changed, low-to-moderate dose of
glucocorticoids1-3 yModerate Therapy with nutritional supplements or
lifestyle improvements1-3 yLow Stability documented on nutritional
supplements or lifestyle improvements
and with no change in clinical status;
drug therapy shown to be effective3-5 yVery low Normal results or low fracture risk and
no clinical risks5-10 yIn some jurisdictions, the timing of follow-up may be
restricted by provincial health insurance plans. In these
circumstances, follow-up recommendations need to be
applied in the context of local restrictions.Appendix 7. Components of a Follow-up Adult Bone
Mineral Density Report
All follow-up adult (age 18 years old or older) bone
mineral density (BMD) reports should include the following
components in this recommended order of presentation:
Demographics
A name
A date of birth
A sex
A provincial health care number or other identifier
A height
A weight
A scan date
A report date
A referring physician
A reporting physician
A facility name and location
Diagnostic Category
Fracture Risk Category (if 50 years of age or older)
History Used for Risk Determination
BMD Data
A BMD
A BMD T-score for those 50 years of age or older/
Z-score for those younger than 50 years old
A reference database used
A Note: For men 50 years of age or older, there will
be 2 sets of femoral neck BMD T-scores and
2 reference databases listed: a white male refer-
ence database for diagnostic categorization and a
white female reference database for risk determina-
tion.Changes in Density
A BMD change
A percentage BMD change
A statistical significance
A least significant change
Limitations
Interpretation
Recommended Follow-up Date
Definitions
Machine Identification
A brand
A model
A serial number
Appendix 8. Components of a First-Time Pediatric Bone
Mineral Density Report
All first-pediatric (under age 18 years) bone mineral
density (BMD) reports should include the following
components in this recommended order of presentation:
Demographics
A name
A date of birth
A sex
A provincial health care number or other identifier
A height
A weight
A scan date
A report date
A referring physician
A reporting physician
A facility name and location
Diagnostic Category
BMD Data
A bone mineral content (BMC)
A BMC Z-score
A adjusted BMC Z-score
A BMD
A BMD Z-score
A adjusted BMD Z-score
A reference database used
Limitations
Interpretation
Definitions
Machine Identification
A brand
A model
A serial number
Appendix 9. Method for Adjusting Z-score for Bone Age
or Height Age
Z-score Adjustment for Bone Age
1. Determine Z-score for all scan sites based on chrono-
logical age.
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3. Use point estimate of bone age to determine ‘‘adjusted
birthdate’’ for patient.
4. If bone age differs from chronological age by more
than 1 year, then change the birthdate to ‘‘adjusted
birthdate’’ in the dual-energy x-ray absorptiometry
(DXA) program and determine adjusted Z-scores for
all scan sites.
5. Report for all scan sites the Z-scores based on chrono-
logical age and the bone age-adjusted Z-scores. If
bone age does not differ from chronological age by
more than 1 year, then this should be noted in the
report and a bone age-adjusted Z-score need not be
reported.
Example
A boy with a birthdate of January 10, 2005; a DXA scan
date of July 10, 2012. Chronological age on the scan date: 7
years 6 months. Z-scores were derived by using the chro-
nological age.
Bone age by wrist radiographs: 5 years 6 months. The
adjusted birthdate assigned as January 10, 2007. Bone-age
adjusted Z-scores were derived by using the bone age.
The report for each skeletal site includes bone mineral
density (BMD) (in g/cm2, to 3 decimal places), the BMD Z-
score (to 1 decimal place), and the bone age-adjusted BMD
Z-score (to 1 decimal place); and bone mineral content
(BMC) (in grams, to 2 decimal places), BMC Z-score (to 1
decimal place), and bone age-adjusted BMC Z-score (to 1
decimal place).
Z-score Adjustment for Height Age
1. Determine Z-score for all scan sites based on chrono-
logical age.
2. Determine ‘‘height age’’ by using growth charts for the
child’s sex (available at www.cdc.gov/GrowthCharts).
3. Measure height 3 times and use the average value as the
patient’s height.
4. By using the patient’s height on the vertical axis of the
Centers for Disease Control (CDC) growth chart, locate
where this height line intersects the 50th percentile
growth curve. By extrapolating to the horizontal axis,
determine the age that corresponds to the point on the
50th percentile growth curve. This is the patient’s
‘‘height age.’’
5. If height age differs from chronological age by more than
1 year, then change the birthdate to ‘‘adjusted birthdate’’
in the DXA program and determine adjusted Z-scores for
all scan sites.
6. Report for all scan sites the Z-scores based on chrono-
logical age and the height age-adjusted Z-scores. If
height age does not differ from chronological age by
more than 1 year, then this should be noted in the
report and a height age-adjusted Z-score need not be
reported.Example
A girl with a birthdate of January 10, 2001. DXA scan
date of July 10, 2012. Chronological age on scan date: 11
years 6 months. Z-scores were derived by using the chro-
nological age.
Height was measured 3 times by using a stadiometer, with
repositioning between measurements: 134.4 cm, 133.8 cm,
135.3 cm; average height of 134.5 cm.
On CDC Growth Chart ‘‘Stature-for-age percentiles: girls,
2 to 20 years,’’ a height of 134.5 cm corresponds to an age of
9 years 3 months at the 50th percentile.
The adjusted birthdate was assigned as April 10, 2003.
The height age-adjusted Z-scores were derived by using
height age.
Report for each skeletal site includes the BMD (in g/cm2,
to 3 decimal places), the Z-score (to 1 decimal place), and
the height age-adjusted Z-score (to 1 decimal place); and the
BMC (in grams, to 2 decimal places), BMC Z-score (to 1
decimal place), and height age-adjusted BMC Z-score (to 1
decimal place).Appendix 10. Components of a Follow-up Pediatric Bone
Mineral Density Report
All follow-up pediatric (under age 18 years) bone
mineral density (BMD) reports should include the
following components in this recommended order of
presentation:
Demographics
A name
A date of birth
A sex
A provincial health care number or other
identifier
A height
A weight
A scan date
A report date
A referring physician
A reporting physician
A facility name and location
Diagnostic Category
BMD Data
A bone mineral content (BMC)
A BMC Z-score
A adjusted BMC Z-score
A BMD
A BMD Z-score
A adjusted BMD Z-score
A reference database used
Changes in Density
A BMC change
A percentage of BMC change
A change in BMC Z-score
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A BMC least significant change (LSC)
A BMD change
A percentage BMD change
A change in BMD Z-score
A statistical significance of BMD change
A BMD LSCLimitations
Interpretation
Definitions
Machine Identification
A brand
A model
A serial number
